QuantRank
Back to ranking
#49USNASDAQ

TGTX

TG Therapeutics, Inc.

$53.95USD

Data as of 2026-07-21

Fair value$19.43
Target$71.21
Loss chance60%Moderate-high

Company attributes

SizeMid cap
SectorHealth Care
Dividend—
TypeCommon stock

Price

Interactive 5-year price history chart for TGTX. Latest close $53.95.

Loading price history…

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=166)
  • Quality
    Profit margins & asset efficiency
    90
    Exceptional
    Health Care median (n=166) 50
  • Value
    Price vs fundamentals
    27
    Weak
    Health Care median (n=166) 52
  • Growth
    Revenue & earnings trajectory
    75
    Exceptional
    Health Care median (n=166) 50
  • Momentum
    Recent price strength
    82
    Exceptional
    Health Care median (n=166) 49
  • Health
    Balance sheet & solvency
    72
    Exceptional
    Health Care median (n=166) 57
  • Profitability
    ROE, ROA, ROIC
    79
    Exceptional
    Health Care median (n=166) 48
  • Technical
    Trend & volatility signals
    49
    Average
    Health Care median (n=166) 56
  • Risk
    Volatility & drawdown profile
    46
    Average
    Health Care median (n=166) 46
025405570100
Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Risk Summary

2 active
Rank gates
  • Sloan accruals — top decile[sloan_accruals_top_decile]Within-sector top decile of accruals / assets (Sloan 1996).
  • Beneish M-score veto[beneish_manipulation_veto]Beneish M-score above −1.78 — earnings manipulation likely (Beneish 1999).

These flags keep the raw composite rank (project Rule 16) but forfeit the entered_top5 badge. Two of them — altman_distress and data_quality_input_corruption — additionally force a cautious recommendation; the others act as Top-5 disqualifiers without dictating the buy/hold/sell label on their own.

Manipulation index
High
56/100
Composite penalty: −5.60 pts (informational; rank uses raw composite)
Also fired — not rank-gating (4)
  • Real Earnings Management (Roychowdhury 2006)[rem_suspect]
  • Restatement history (10-K/A, 5y)[restatement_history]
  • Accruals momentum (Δ TATA > 0.05 over 3y)[accruals_momentum_high]
  • Beneish M-score warning band[beneish_high]

Rolls up Phase 4.5 earnings-manipulation defenses (Sloan · Beneish · Dechow · REM · restatement · late-filing · earnings- quality time-series) into a single 0-100 risk index. The soft composite penalty (max 10 pts) is informational only — the ranking uses the raw composite score per project Rule 16.

Fair price check

5 different valuation methods each estimate what TGTXshould be worth, then we compare to today's price.

Heavily overvalued
Models suggest TGTX is far above estimated fair value
Today's price
$53.95
Median fair price
$19.43
-64% vs today's price
Of 3 methods:1 say cheap2 say pricey(2 outliers excluded)
  • P/E multiplesUndervalued
    thinks it's a bargain — estimates $71.21, about 32% above today
  • EV/EBITDAOvervalued
    thinks it's expensive — estimates $23.48, about 56% below today
  • P/B multiplesOvervalued
    thinks it's expensive — estimates $19.43, about 64% below today
  • Graham (defensive)Outlier
    estimate looks unreliable — estimates $9.27 — likely unreliable
  • Residual IncomeOutlier
    estimate looks unreliable — estimates $8.29 — likely unreliable

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair
$19.43
Margin of safety(vs fair value)
< −99%
Max (ex-outliers)
$71.21
Tangible BVPS
$3.80
  • Extreme Graham estimate
  • Extreme Residual-Income estimate
  • Beneish M-score (warning band)
  • Restatement history
  • Real Earnings Management
  • Accruals momentum

Median of all applicable methods (current price $53.95). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

MetricValue
Market cap$8.26B
Revenue (TTM)$700.35M
Net income (TTM)$461.90M
Operating cash flow (TTM)$-19.51M
CapEx (TTM)$240.00K
Free cash flow (TTM)CFO − CapEx$-19.75M
Total assets$1.53B
Total liabilities$945.71M
Stockholders' equity$583.13M
Cash & equivalents$442.21M
Shares outstanding153.08M
EPS (basic)$3.02
EPS (diluted)$3.02
P/E ratio (TTM)17.88

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date
2026-05-06
Latest period end
2026-05-01
Filing lag
76 days
Missing metrics
4(gross_profit, dividends_paid, accounts_payable, intangibles_net)

Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.